In this episode:00:52 Testing disparitiesAs testing capacities increase, it is clear that not everyone has equal access. But grassroots organisations are trying to correct this inequity. We hear about one researcher’s fight to get testing to those below the poverty line in California.09:04 The hydroxychloroquine saga continuesAs a high profile study in the Lancet is retracted, the first data from clinical trials is coming in and it is not encouraging. We discuss the murky future of hydroxychloroquine as a COVID drug.News: High-profile coronavirus retractions raise concerns about data oversight12:31 Will the Surgisphere scandal erode trust in science?A questionable dataset from a mysterious company has forced high-profile retractions and thrown doubt over drug trials and public health policies. What will the fallout be and can researchers weather the storm?23:23 Back in the labAs lockdowns ease, researchers are starting to go back to the lab. But with various restrictions in place, what does science look like in the new normal?News: Return to the lab: scientists face shiftwork, masks and distancing as coronavirus lockdowns easeCareers: Coronavirus diaries: back to the lab again Hosted on Acast. See acast.com/privacy for more information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.